[{"uuid": "c7420e5f-e761-38cd-983f-1967312fac06", "title": "Update on regulatory review of lecanemab for treatment of early Alzheimer's disease in the European Union", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/regulatory-review-lecanemab-treatment-early-121500366.html", "providerPublishTime": 1738325700, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ucwI9Nn3AbEI2eYhriEKXQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/36000ee9437e89d3396fb62789a4b75a", "width": 16, "height": 16, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/KYovyIg7AIfblpL13rRIUA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/36000ee9437e89d3396fb62789a4b75a", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "224cc50f-5922-3828-af30-c696171231b1", "title": "BioAge Labs Terminates Azelapra Development", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/bioage-labs-terminates-azelapra-development-153522655.html", "providerPublishTime": 1738078522, "type": "STORY", "relatedTickers": ["BIOA"]}, {"uuid": "e64384cb-61ef-3fde-86f7-0be3c6ea7f84", "title": "BioAge drops obesity drug; Akero, 89bio cash in on MASH data", "publisher": "BioPharma Dive", "link": "https://finance.yahoo.com/m/e64384cb-61ef-3fde-86f7-0be3c6ea7f84/bioage-drops-obesity-drug%3B.html", "providerPublishTime": 1738147185, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/H45ciFL01k8pIJfsr8ZYEA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259", "width": 1600, "height": 900, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/m8gMMn1cTlFUNNLyoWoNVA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BIOA", "AKRO", "VNDA", "ALLK"]}, {"uuid": "95c75d90-592a-3097-80a5-aa1312177fb7", "title": "BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/bioage-labs-announces-company-updates-140000896.html", "providerPublishTime": 1738072800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LmnXv7Eg5.BtETrtf4a1Dg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c7c3eca4813d4b0721cab9b693b5c572", "width": 500, "height": 500, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/HYxGkf_Ze84Bt7QUkNl8YA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c7c3eca4813d4b0721cab9b693b5c572", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BIOA"]}, {"uuid": "319a8ee5-2d48-38db-a59d-eb2f90dc6254", "title": "FDA approves IV maintenance dosing of Leqembi\u00ae (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/fda-approves-iv-maintenance-dosing-025300601.html", "providerPublishTime": 1737946380, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/M4Iolo9lLEIJ899KHXeKag--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/4557b5ce1e5d67bcf915e2f2eefbfefb", "width": 16, "height": 16, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/iJvWRFnSSVR7_b6m_mMWLw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/4557b5ce1e5d67bcf915e2f2eefbfefb", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BRCTF"]}, {"uuid": "4cbc0c0a-42ef-32a2-9fc7-e252a39dc95f", "title": "3 Growth Companies Insiders Own With Earnings Growth Up To 51%", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/3-growth-companies-insiders-own-050143254.html", "providerPublishTime": 1737954103, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/d4E4P3C1gbs8FgjLBwQDxQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/de3693c96ca28c16427680d76341d044", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1NhR10SDcMRWs7cFC1fJiA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/de3693c96ca28c16427680d76341d044", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["HMNKF", "BRCTF"]}, {"uuid": "e6d74917-079e-3836-bbad-46db35549d44", "title": "Tikehau Capital And 2 More Stocks That May Be Priced Below Their Estimated Worth", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/tikehau-capital-2-more-stocks-050237352.html", "providerPublishTime": 1737954157, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SSw8naZrBB1tKswm10P8gw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f88d3d8c5618aa88ce2627c2a1cda340", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.II968g4CKL3EwcBRm6Chg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f88d3d8c5618aa88ce2627c2a1cda340", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BRCTF", "TKKHF"]}, {"uuid": "4d22491b-cf10-34e6-9163-6c431c763ef8", "title": "After an obesity stumble, BioAge reconnects with its longevity pipeline", "publisher": "Pharma Voice", "link": "https://finance.yahoo.com/m/4d22491b-cf10-34e6-9163-6c431c763ef8/after-an-obesity-stumble%2C.html", "providerPublishTime": 1737532800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/JDXLduIcc_MHKs4Cv2pGYg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/ebe272ab58bd5f4860f49994e2412f2a", "width": 1280, "height": 720, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/cuvbLlOlbSceNbN3YhwgRg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/ebe272ab58bd5f4860f49994e2412f2a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BIOA", "NVS"]}, {"uuid": "81059ceb-8d48-3ec6-8a55-c5d4d198b245", "title": "FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi\u00ae (lecanemab-irmb) in the US", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/fda-accepts-biologics-license-application-025100211.html", "providerPublishTime": 1736823060, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/S2ctkCwNJLeqYTkVxsX2nw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/0f583bca3cfa2829872e75ec3cfd81c8", "width": 16, "height": 16, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.n8btFL7zIkMnPomhcjvIA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/0f583bca3cfa2829872e75ec3cfd81c8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BRCTF"]}, {"uuid": "1c836965-3ec6-326b-b9cf-e36d4204bf0c", "title": "BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/bioage-labs-inc-bioa-loses-143506211.html", "providerPublishTime": 1735828506, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/jF7zhMBLKS5JRTJW0pizBQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BIOA"]}, {"uuid": "dd273e2f-860a-3cbb-be63-5c0a69ab3a3b", "title": "High Growth Tech Stocks To Watch In January 2025", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/high-growth-tech-stocks-watch-010246413.html", "providerPublishTime": 1736384566, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/plucjPvNVLzjefg0FeX3dA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f315d7e0744651426b23f302f8c1adc6", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/DvzeQiKHQfr_sN827IfTOA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f315d7e0744651426b23f302f8c1adc6", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BRCTF", "HMNTY"]}, {"uuid": "31af8acc-1249-3d31-8feb-d93fa4346f41", "title": "BioAge Labs, Inc. (BIOA): A Bull Case Theory", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/bioage-labs-inc-bioa-bull-141831408.html", "providerPublishTime": 1735309111, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/UQktL66bQ94v0aVuCuTMVQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bad97a50c8c8b61ee2e24d1733d817dc", "width": 768, "height": 430, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/cMXx8RcUf4G4RdQqwrtZ6g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/bad97a50c8c8b61ee2e24d1733d817dc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BIOA"]}]